Quantum-Si, Inc. (QSI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.77+0.66%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · QSI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 425.9% |
| Our one-year growth estimate | diamond | -24.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 450.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
QSI — capital allocation — Creation of a Direct Financial Obligation or an Obligation Under an Off-Balan…
Dated 2026-06-24
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information included in
Why it matters: Staying under this limit is key for operations and funding. It shows good financial control.
Worry ifTotal cash usage reported at or below $93 million for 2026.
Less concerning ifTotal cash usage exceeds $93 million for 2026.
Why it matters: Keeping expenses in check is key to meeting the $98 million target for the year. This shows financial discipline.
Supportive ifOperating costs were under $25 million for Q2.
Worry ifOperating costs went over $25 million in Q2. This shows issues with cost control.
Why it matters: Allowing customer evaluations shows that Proteus is ready to launch. This may help investors.
Supportive ifThey announced early access sites for customer sample tests with Proteus tools.
Worry ifNo early access sites were announced. This shows delays in Proteus readiness.
Why it matters: The earnings beat shows possible positive momentum. It may show better investor confidence.
Supportive ifWatch for news or press releases that confirm good performance.
Worry ifNo further positive updates or a return to losses.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$276 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $804 loss on $10,000 · 8.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,330 loss on $10,000 · 73.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If health care revenue growth speeds up, it could lift Quantum-Si's prospects. This would indicate a healthier market.
Supportive ifHealth care sector revenue growth is speeding up again. It is getting close to 10% each year.
Worry ifHealth care sector revenue growth continues to decelerate below 5% year over year.
Why it matters: A drop in revenue would show ongoing struggles in a maturing sector. Investors will react to signs of weakness.
Worry ifQ2 earnings report shows revenue declining year over year by more than 10%.
Less concerning ifQ2 earnings report shows revenue growth year over year or stabilizes.
Why it matters: Success in this market could significantly boost Quantum-Si's growth potential. It shows market expansion.
Supportive ifLook for new customer deals or contracts in non-human proteomics.
Worry ifNo new deals or partnerships in the non-human proteomics market.
Why it matters: The lease for new office and lab space could support growth and operations.
Supportive ifOfficial announcement detailing plans for the new space and its use.
Worry ifThere are no updates or delays in the lease agreement.
Why it matters: Hitting this revenue target is key for proving the Proteus transition plan.
Supportive ifQ3 revenue is $1 million or more, showing the transition is working.
Worry ifQ3 revenue is below $1 million, showing problems with the transition.
Why it matters: The launch of Proteus is crucial for Quantum-Si's growth. Delays could impact future revenue.
Supportive ifFinish the new instrument design cycle before Q2 2027.
Worry ifFurther delays in the launch timeline beyond Q2 2027.
Why it matters: Staying under this target shows effective cost management, which is crucial for cash runway.
Supportive ifTotal operating costs will be $98 million or less for 2026.
Worry ifTotal operating costs will be more than $98 million for 2026.
Why it matters: Clear updates on the launch timeline help investors know what to expect. They also help with market plans.
Watch forAnnouncement of a specific launch date for the Proteus system.
Also watch forNo updates on the launch timeline may mean delays are possible.
Why it matters: Meeting this goal shows progress in moving to the Proteus platform.
Supportive ifRevenue reported at or above $1 million for the full year 2026.
Worry ifRevenue reported below $1 million for the full year 2026.
Why it matters: The launch of Proteus is key for revenue growth. Delays could impact investor confidence.
Worry ifManagement confirms the Proteus launch remains on track for Q2 2027 without further delays.
Less concerning ifManagement delays the Proteus launch past Q2 2027 or reports big setbacks.
Why it matters: Cost savings help improve financial health. They also support Proteus development.
Supportive ifManagement says cost cuts were successful and savings were achieved.
Worry ifManagement says cost cuts did not bring the expected savings.
Why it matters: Keeping a strong cash position is important for funding Proteus work.
Supportive ifManagement says cash runway lasts into Q4 2028 without needing more funds.
Worry ifManagement says cash runway is shorter than expected or needs more funding.